Implementation of Quality by Design for the Development and Validation of Pioglitazone Hydrochloride by RP-UPLC with Application to Formulated Forms

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="592849.fig.006a" src="https://static.hindawi.com/articles/isrn/volume-2012/592849/figures/592849.fig.006a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>Placebo blank</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="592849.fig.006b" src="https://static.hindawi.com/articles/isrn/volume-2012/592849/figures/592849.fig.006b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>Tablet extract</td></tr></table></td></tr></table>

<table>Chromatograms obtained for placebo blank and tablet extract.</table>

International Scholarly Research Notices

fig6

Figure 6

Figure 6: Implementation of Quality by Design for the Development and Validation of Pioglitazone Hydrochloride by RP-UPLC with Application to Formulated Forms 

Figure 6 | Implementation of Quality by Design for the Development and Validation of Pioglitazone Hydrochloride by RP-UPLC with Application to Formulated Forms 